NASDAQ:TARA

Protara Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TARA

*Your capital is at risk

$4.22

-0.120 (-2.76%)

At Close: Jun 03, 2026

Protara Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 68.17. In total, the insiders bought 4.48M and sold 814.4K TARA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	68.17
● Buy	4.48M shares
● Sell	814.4K shares
66% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Apr 01, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 68.17. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 08, 2026 Sell	Common Stock S-Sale	Zummo Jacqueline Chief R&d Officer	Officer	1 134 Value: $6K
Apr 01, 2026 Sell	Common Stock S-Sale	Zummo Jacqueline Chief R&d Officer	Officer	22 598 Value: $118.9K
Jan 26, 2026 Sell	Common Stock F-InKind	Fry Hannah Vp, Controller	Officer	1 457 Value: $10K
Jan 26, 2026 Sell	Common Stock F-InKind	Fabbio Patrick Chief Financial Officer	C-Suite Officer	3 261 Value: $21.8K
Jan 26, 2026 Sell	Common Stock F-InKind	Shefferman Jesse CEO And President	CEO / President	8 732 Value: $58.2K
Jan 26, 2026 Sell	Common Stock F-InKind	Zummo Jacqueline Chf Scientific Operations Off	Officer	3 724 Value: $24.8K
Jan 20, 2026 Sell	Common Stock F-InKind	Fry Hannah Vp, Controller	Officer	2 132 Value: $11.9K
Jan 20, 2026 Sell	Common Stock F-InKind	Zummo Jacqueline Chf Scientific Operations Off	Officer	6 578 Value: $36.8K
Jan 20, 2026 Sell	Common Stock F-InKind	Fabbio Patrick Chief Financial Officer	C-Suite Officer	3 063 Value: $17.2K
Jan 20, 2026 Sell	Common Stock F-InKind	Shefferman Jesse CEO And President	CEO / President	16 322 Value: $91.4K
Jan 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Shefferman Jesse CEO And President	CEO / President	524 000 Value: $2.63M
Jan 16, 2026 Buy	Common Stock A-Award	Nicacio Leonardo Viana Chief Medical Officer	Officer	26 000 Value: $130.3K
Jan 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Nicacio Leonardo Viana Chief Medical Officer	Officer	158 000 Value: $791.6K
Jan 16, 2026 Buy	Common Stock A-Award	Fry Hannah Vp, Controller	Officer	9 500 Value: $47.6K
Jan 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Fabbio Patrick Chief Financial Officer	C-Suite Officer	175 000 Value: $876.8K
Jan 16, 2026 Buy	Common Stock A-Award	Conkling William Chief Commercial Officer	Officer	26 000 Value: $130.3K
Jan 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Conkling William Chief Commercial Officer	Officer	158 000 Value: $791.6K
Jan 16, 2026 Buy	Common Stock A-Award	Fabbio Patrick Chief Financial Officer	C-Suite Officer	28 000 Value: $140.3K
Jan 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Fry Hannah Vp, Controller	Officer	55 000 Value: $275.6K
Jan 16, 2026 Buy	Common Stock A-Award	Shefferman Jesse CEO And President	CEO / President	87 000 Value: $435.9K
Jan 16, 2026 Buy	Stock Option (Right to Buy) A-Award	Zummo Jacqueline Chf Scientific Operations Off	Officer	180 000 Value: $901.8K
Jan 16, 2026 Buy	Common Stock A-Award	Zummo Jacqueline Chf Scientific Operations Off	Officer	30 000 Value: $150.3K
Jun 27, 2025 Sell	Common Stock G-Gift	Shefferman Jesse CEO And President	CEO / President	10 200 Value: $0
Jun 27, 2025 Sell	Common Stock G-Gift	Shefferman Jesse CEO And President	CEO / President	3 367 Value: $0
Jun 27, 2025 Sell	Common Stock G-Gift	Shefferman Jesse CEO And President	CEO / President	3 367 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROTARA THERAPEUTICS, INC.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failur...

Read Full Profile Here